Sumitomo Pharma Co Ltd
TSE:4506

Watchlist Manager
Sumitomo Pharma Co Ltd Logo
Sumitomo Pharma Co Ltd
TSE:4506
Watchlist
Price: 568 JPY -0.53% Market Closed
Market Cap: 226B JPY
Have any thoughts about
Sumitomo Pharma Co Ltd?
Write Note
Sumitomo Pharma Co Ltd
/
Balance Sheet
/
Current Portion of Long-Term Debt

Sumitomo Pharma Co Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sumitomo Pharma Co Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Sumitomo Pharma Co Ltd
TSE:4506
Current Portion of Long-Term Debt
¥256B
CAGR 3-Years
113%
CAGR 5-Years
144%
CAGR 10-Years
38%
Takeda Pharmaceutical Co Ltd
TSE:4502
Current Portion of Long-Term Debt
¥624.1B
CAGR 3-Years
43%
CAGR 5-Years
29%
CAGR 10-Years
14%
Daiichi Sankyo Co Ltd
TSE:4568
Current Portion of Long-Term Debt
¥400m
CAGR 3-Years
-73%
CAGR 5-Years
-60%
CAGR 10-Years
-43%
Otsuka Holdings Co Ltd
TSE:4578
Current Portion of Long-Term Debt
¥191.2B
CAGR 3-Years
57%
CAGR 5-Years
20%
CAGR 10-Years
9%
Chugai Pharmaceutical Co Ltd
TSE:4519
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Current Portion of Long-Term Debt
¥307.3B
CAGR 3-Years
43%
CAGR 5-Years
47%
CAGR 10-Years
45%
No Stocks Found

Sumitomo Pharma Co Ltd
Glance View

Market Cap
225.7B JPY
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Sumitomo Pharma Co. Ltd. stands as a testament to innovation and resilience. Emerging from its roots in Sumitomo Dainippon Pharma, this Japanese giant has been weaving a complex tapestry of cutting-edge medical advancements and strategic mergers for decades. At its core, Sumitomo Pharma is fueled by an unwavering commitment to research and development, driving its efforts in therapeutic areas such as psychiatry, neurology, and oncology. These focal points aren't mere business segments but vital lifelines that the company seeks to improve with its products. Their success heavily relies on their ability to translate research into actionable, marketable treatments; it's a dance between science and commerce, with the rhythm dictated by patient needs and market demands. Sumitomo Pharma's financial engine is powered not just by their innovative drug pipeline but also through savvy global partnerships and strategic acquisitions. By expanding its footprint across North America, Europe, and Asia, the company meticulously builds a global distribution network that ensures its products reach the hands of physicians and patients worldwide. This extensive reach allows Sumitomo Pharma to tap into diverse markets, fueling both sales and brand recognition. Moreover, through its alliances with biotech firms and academic institutions, the company enhances its research capabilities, fostering a cycle of innovation that feeds back into its financial growth. In essence, Sumitomo Pharma doesn't just participate in the pharmaceutical industry; it actively shapes it, both through its dedication to breakthrough therapies and its strategic navigation of complex global markets.

Intrinsic Value
776.5 JPY
Undervaluation 27%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Sumitomo Pharma Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
256B JPY

Based on the financial report for Sep 30, 2024, Sumitomo Pharma Co Ltd's Current Portion of Long-Term Debt amounts to 256B JPY.

What is Sumitomo Pharma Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
38%

Over the last year, the Current Portion of Long-Term Debt growth was 83%. The average annual Current Portion of Long-Term Debt growth rates for Sumitomo Pharma Co Ltd have been 113% over the past three years , 144% over the past five years , and 38% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.